Bimekizumab versus Secukinumab in Plaque Psoriasis

In this RCT, bimekizumab resulted in greater skin clearance than secukinumab at week 16 (n=743; 61.7% vs 48.9% achieved PASI 100 response; risk difference, 12.7%; 95% CI, 5.8 to 19.6; P<0.001 for noninferiority and superiority).

Source:

New England Journal of Medicine